December 11, 2013

Direct-to-Consumer Genetic Testing: Let the Debate Begin

Overview

The FDA’s recent warning letter to 23andMe, the maker of mail-order genetic tests, highlights the challenging legal and ethical issues posed by direct-to-consumer genetic testing. 

We’ve been discussing this trend on our Life Sciences Industry blog, www.lifesciencesnow.com, and dove deeper into these issues during our complimentary webinar on Thursday, December 12.

In addition to discussing the specifics of the FDA’s recent action, we also discussed First Amendment issues related to FDA regulation of DTC genetic testing, and explore consent and privacy topics.

Specific questions that were debated and discussed include:

  • Should direct-to-consumer genetic testing be regulated as the practice of medicine?
  • Should DTC genetic tests be regulated as a medical device?
  • Are there adequate privacy protections for DTC genetic test information?
  • What perspectives do consumers have on these issues?
  • What positions do professional organizations take on the issue?

Panelists for the event included Drinker Biddle lawyers Kenneth Wilbur and Fatema Zanzi. Our discussion was moderated by Robyn Shapiro.

Services and Industries

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.